The earnings call presented both significant advancements in clinical trials and a strong financial position, but these were offset by increased expenses and net loss. The progress in clinical programs, particularly the VK2735 obesity program, is promising, but financial challenges remain.

Company Guidance

During the Viking Therapeutics Second Quarter 2025 Financial Results Conference Call, Viking provided detailed guidance on its ongoing clinical development activities and financial outcomes. The company highlighted significant progress in its VK2735 obesity program, including the initiation of the VANQUISH Phase III registration program for its subcutaneous formulation and the completion of enrollment in a Phase II trial for the oral formulation. Viking also advanced its novel amylin receptor agonist program, with plans to file an IND in the fourth quarter. Financially, Viking reported increased research and development expenses of $60.2 million for Q2 2025, up from $23.8 million in Q2 2024, and a net loss of $65.6 million or $0.58 per share, compared to a net loss of $22.3 million or $0.20 per share in the prior year period. The company maintained a strong cash position with $808 million in cash, cash equivalents, and short-term investments as of June 30, 2025, to support its ongoing and future clinical programs.

Advancement of VK2735 into Phase III

Viking Therapeutics has initiated the VANQUISH Phase III registration program for VK2735 in patients with obesity. This includes trials for adults with obesity and those with obesity and type 2 diabetes, targeting enrollment of approximately 4,500 and 1,100 participants, respectively.

Successful Phase II Results for VK2735

The VENTURE Phase II study achieved primary and secondary endpoints with subjects showing statistically significant reductions in mean body weight from baseline, up to 14.7%, demonstrating VK2735's efficacy in weight loss.

Strong Financial Position

Viking Therapeutics holds $808 million in cash, cash equivalents, and short-term investments as of June 30, 2025, providing financial runway to complete Phase III trials for VK2735 and pursue additional programs.

Progress on Amylin Agonist Program

Viking made progress on its novel agonist targeting the amylin receptor, with plans to file an IND in the fourth quarter of 2025.

Viking Therapeutics (VKTX) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

VKTX Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 22, 2025	2025 (Q3)	-0.70 / -	-0.22	―	―	―
Jul 24, 2025	2025 (Q2)	-0.45 / -0.58	-0.2	-190.00% (-0.38)	―
Apr 23, 2025	2025 (Q1)	-0.33 / -0.41	-0.26	-57.69% (-0.15)	―
Feb 05, 2025	2024 (Q4)	-0.28 / -0.32	-0.25	-28.00% (-0.07)	―
Oct 23, 2024	2024 (Q3)	-0.24 / -0.22	-0.23	4.35% (+0.01)	―
Jul 24, 2024	2024 (Q2)	-0.26 / -0.20	-0.19	-5.26% (-0.01)	―
Apr 24, 2024	2024 (Q1)	-0.28 / -0.26	-0.25	-4.00% (-0.01)	―
Feb 07, 2024	2023 (Q4)	-0.25 / -0.25	-0.26	3.85% (+0.01)	―
Oct 25, 2023	2023 (Q3)	-0.22 / -0.23	-0.21	-9.52% (-0.02)	―
Jul 26, 2023	2023 (Q2)	-0.19 / -0.19	-0.23	17.39% (+0.04)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

VKTX Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 24, 2025	$33.50	$34.42	+2.75%
Apr 23, 2025	$25.79	$25.66	-0.50%
Feb 05, 2025	$33.50	$31.46	-6.09%
Oct 23, 2024	$60.39	$73.22	+21.25%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Viking Therapeutics (VKTX) report earnings?

Viking Therapeutics (VKTX) is schdueled to report earning on Oct 22, 2025, After Close (Confirmed).

What is Viking Therapeutics (VKTX) earnings time?

Viking Therapeutics (VKTX) earnings time is at Oct 22, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is VKTX EPS forecast?

VKTX EPS forecast for the fiscal quarter 2025 (Q3) is -0.7.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing